The Biology of Late-Life Depression

  • Charles B. Nemeroff
  • P. Rodrigo Escalona
  • K. Ranga
  • R. Krishnan
  • Charles F. ReynoldsIII
Part of the The Depressive Illness Series book series (DISS, volume 4)

Abstract

Current evidence suggests that depression is clearly not a single entity but a syndrome characterized by a broad spectrum of symptom type and severity, and chronicity of illness. Depression is one of the most frequent psychiatric disorders in the geriatric population, though figures of prevalence have ranged from 5 to 44% depending on the method of identification (Blazer & Williams, 1980). Interestingly, data from the ECA study revealed that the lifetime prevalence of depression was four times lower in persons aged 65 years or older than in individuals aged 25 to 44 at the time of the ECA (Myers, Weissman, Tischer, et al., 1984). However, Berkman et al. (1986) obtained data to support the view that the presence of significant depressive symptoms, but not major depression, are more frequent among the elderly. In that study only 1–2% of the subjects fulfilled DSM III criteria for major depression but more than 10% had depressive symptoms. It is unclear at the present time whether those depressive symptoms are largely due to psychosocial factors, biological factors, or a combination of the two. Several investigators have suggested that depression in late life is a distinct entity from depression in early life. Genetic predisposition seems to play only a modest role in the aethiopathogenesis of geriatric depression when compared with a younger age group (Hopkinson, 1964; Mendlewicz, 1976).

Keywords

Depressed Patient Bioi Psychiatry Elderly Depressed Patient Late Onset Depression Urinary MHPG 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexopoulos GS, Lieberman KW, Young RC, et al: Platelet MAO activity and age of onset of depression in elderly depressed women. Am J Psychiatry 1984; 141: 1276–1278.PubMedGoogle Scholar
  2. Asberg M, Theren P, Traskman L, Bertilson L, Ringsberger K: Serotonin depression, A biochemical subgroup within the affective disorders? Science 1976; 191: 478.PubMedCrossRefGoogle Scholar
  3. Ashcroft GW, Crawford TBB, Eccleston et al: 5-Hydroxyindole compounds in cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet 1966, ii; 1049.Google Scholar
  4. Awad IA, Spetzler RF, Hodak JA, et al: Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. Correlation with age and cerebrovascular risk factors. Stroke 1986; 17: 1084–1089.PubMedCrossRefGoogle Scholar
  5. Banki CM, Bissette GB, Arato MA, O’Connor L, Nemeroff CB: CSF corticotropinreleasing-factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144: 873–877.PubMedGoogle Scholar
  6. Banki CM, Bissette G, Arato M, Nemeroff CB: Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry 1988; 145: 1526–1531.PubMedGoogle Scholar
  7. Baron M, Rish N, Hamburger R, et al: Genetic linkage between X-chromosome markers and bipolar affective illness. Nature 1987; 326: 289–292.PubMedCrossRefGoogle Scholar
  8. Berkman LF, Berkman CS, Casl S, et al: Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol 1986; 124: 372–388.PubMedGoogle Scholar
  9. Biegnon A, Grinspoon A, Blumerfeld B, Bleich A, Apter A, Mester R: Increased serotonin 5HT2 receptor binding on blood platelets of suicidal men. Pharmacology 1990; 140: 165–167.Google Scholar
  10. Blazer D, Williams CD: Epidemiology of dysphoria and depression in an elderly community population. Am J Psychiatry 1980; 137: 439–444.PubMedGoogle Scholar
  11. Bourne HR, Bunney Jr WE, Colburn RW, et al: Noradrenalin, 5-hydroxytrypta-Google Scholar
  12. mine and 5HIAA in midbrains of suicidal patients. Lancet 1968; ii: 805. Buysse EW, Blazer DG, Handbook of Geriatric Psychiatry. New York: Van Nostrand Reinhold, 1980.Google Scholar
  13. Buysse DJ, Reynolds DF, Houck PR, et al: Age of illness onset and sleep EEG variables in elderly depressives. Biol Psychiatry 1988; 24: 355–359.PubMedCrossRefGoogle Scholar
  14. Carroll BJ, Curtis GC, Davies BM, et al: Urinary free cortisol excretion in depression. Psychol Med 1976; 6: 43–50.PubMedCrossRefGoogle Scholar
  15. Carroll BJ: The dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140: 292–304.PubMedCrossRefGoogle Scholar
  16. Checkley SA, Slade AP, Shur P: Growth hormone and other responses to clonidine in patients with endogenous depression. Br J Psychiatry 1988; 138: 51–55.CrossRefGoogle Scholar
  17. Coffey CE, Figiel GS, Djang WT, et al: Leukoencephalopathy in elderly depressed patients referred to ECT. Biol Psychiatry 1988; 24: 143–161.PubMedCrossRefGoogle Scholar
  18. Cohn CK, Dunner DL, Axelrod J: Reduced catechol-O-methyltransferase activity in red blood cells of women with primary affective disorder. Science 1970; 170: 1323.PubMedCrossRefGoogle Scholar
  19. Davis KL, et al: Physostigmine: Improvement of long term memory processes in normal humans. Science 1978; 201: 272.PubMedCrossRefGoogle Scholar
  20. Deicken RF, Reus VI, Manfredi L, Wolkowitz O: MRI deep white matter hyper- intensity in a psychiatric population. Biol Psychiatry 1991; 29: 918–922.PubMedCrossRefGoogle Scholar
  21. Dencker SJ, Malm M, Roos BE, Werdinius B: Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. J Neurochem 1966; 13: 1545.PubMedCrossRefGoogle Scholar
  22. Doraiswamy M, Shah SA, Figiel GS, et al: Hippocampal pathology in major depression. American Psychiatry Association 143rd New York (Abstract). 1990.Google Scholar
  23. Dunner DL, Levitt M, Kumbaraci T, Fieve RR: Erythrocyte catechol-O-methyltransferase activity in primary affective disorder. Biol Psychiatry 1977; 12: 237.PubMedGoogle Scholar
  24. Evans DL, Burnett GB, Nemeroff CB: The dexamethasone suppression test in the clinical setting. Am J Psychiatry 1983; 140: 586–589.PubMedGoogle Scholar
  25. Evans DL, Nemeroff CB: The clinical use of the dexamethasone suppression test in DSM-II affective disorders: Correlation with the severe depressive subtypes of melancholia and psychosis. J Psychiat Res 1987; 21: 185–194.PubMedCrossRefGoogle Scholar
  26. Figiel GS, Krishnan KRR, Breitner JC, and Nemeroff CB: Radiologic correlates of antidepressant-induced delirium: the possible significance of basal ganglia lesions. J Neuropsychiat Clin Neurosci 1989; 1: 188–190.Google Scholar
  27. Figiel GS, Krishnan KRR, Doraiswamy M, and Nemeroff CB: Caudate hyper-intensities in elderly depressed patients with neuroleptic-induced parkinsonism. J Geriat Psychiat Neurol 1991; 4: 86–89.CrossRefGoogle Scholar
  28. Fukushima DK, Gallagher RF: Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1970; 28: 289–298.Google Scholar
  29. Gold MS, Pottash AC, and Extein I: Symptomless autoimmune thyroiditis in depression. Psychiat Res 1982; 6: 261–289.CrossRefGoogle Scholar
  30. Gold PW, Chrousos GP, Kellner CH, et al: Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984; 141: 619–627.PubMedGoogle Scholar
  31. Goodwin FK, Prange AJ, Post RM: L-triiodothyronine converts tricyclic antide- pressant nonresponders to responders. Am J Psychiatry 1982; 139: 37–42.Google Scholar
  32. Haggerty JJ, Simon JS, Evans DL, and Nemeroff CB: Relationship of serum TSH concentration and antithyroid antibodies to diagnosis and DST response in psychiatric inpatients. Am J Psychiatry 1987; 144: 1591–1594.Google Scholar
  33. Haggerty JJ, Evans DL, Golden RN, Pedersen CA, Simon JS, and Nemeroff CB: The presence of anti-thyroid antibodies in patients with affective and non-affective psychiatric disorders. Biol Psychiatry 1990; 27: 51–60.PubMedCrossRefGoogle Scholar
  34. Haggarty JJ Jr, Garbutt JC, Simon JS, et al: Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiat Med 1990; 20: 193–208.CrossRefGoogle Scholar
  35. Hock CC, Reynolds CF, Houck RP, et al: Predicting mortality in mixed depression and dementia using sleep EEG variables. J Neuropsychiat Clin Neurosci 1989; 1: 366–371.Google Scholar
  36. Holsboer F, von Bardeleben U, Gerken A, et al: Blunted corticotropin and normal cortisol response to human corticotropin releasing factor in depression. N Engl J Med 1984; 311: 1137.CrossRefGoogle Scholar
  37. Hopkinson GA: A genetic study of affective illness in patients over 50. Br J Psychiatry 1964; 110: 244.PubMedCrossRefGoogle Scholar
  38. Husain MM, Doraiswamy PM, Figiel GS, et al: Platelet 13H1-imipramine binding and leukoencephalopathy in geriatric depression. Biol Psychiatry 1991; 29: 665–670.PubMedCrossRefGoogle Scholar
  39. Janowsky DS, et al: Cholinergic reversal of manic symptoms. Lancet 1972; is 1236. Janowsky DS, Davis JM, El-Yousef MK, Sekerte HJ: Acetylcholine and depression. Psychosomatic Med 1973; 35: 568.Google Scholar
  40. Jungue C, Pujor J, Vendrell P, et al: Leukoaraiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990; 47: 151–156.CrossRefGoogle Scholar
  41. Kastin AJ, Schalch DS, Ehrensing RH, Anderson MS: Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone. Lancet 1972; 2: 740–742.PubMedCrossRefGoogle Scholar
  42. Kirkegaard C, Faber J, Hummer L, Rogowski P: Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 1979; 4: 227–235.PubMedCrossRefGoogle Scholar
  43. Krishnan KRR: Neuropathology of depression in the elderly: Neuroanatomical substrates. J Geriat Psychiatry (in press).Google Scholar
  44. Krishnan KRR, Manepalli AN, Ritchie JC, et al: Growth hormone-releasing factor stimulation test in depression. Am J Psychiatry 1987; 145: 90–92.Google Scholar
  45. Krishnan KRRR, Goli V, Ellinwood, et al: Leukoencepthalopathy in patients diagnosed as major depressive. Biol Psychiatry 1988; 23: 519–522.PubMedCrossRefGoogle Scholar
  46. Krishnan KRR: Organic bases of depression in the elderly. Ann Rev Med 1990; 42: 261–266.CrossRefGoogle Scholar
  47. Kupfer DJ, Reynolds CF: Sleep and affective disorders. In: Paykel E (Ed.), Handbook of Affective Disorders: Second Edition, New York: Churchill Livingstone, 1992, pp 311–323.Google Scholar
  48. Lesch KP, Laux G, Pfuller H, Erb A, Beckmann H: Growth hormone response to GH-releasing hormone in depression. J Clin Endocrinol Metab 1987; 65: 1278–1281.PubMedCrossRefGoogle Scholar
  49. Lipton MA, Nemeroff CB: The biology of aging and its role in depression. In: Usdin G, Hofling CK (Eds.) Aging: The Process and the People New York: Brunner/Mazel, 1978, 47–95.Google Scholar
  50. Lloyd KG, Farley IJ, Deck LHN, et al: Serotonin and 5HIAA in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol 1974; 11: 387.PubMedGoogle Scholar
  51. Lonergan ET, Ed: Enhancing Life. Committee on a National Research Agenda on Aging. Washington, D.C., Institute of Medicine, National Academy of Science Press, 1991.Google Scholar
  52. Mann JJ, Stanley M, McBride PA, McEwen BS: Increased serotonin2 and ßadrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43: 954–959.PubMedCrossRefGoogle Scholar
  53. Maubach M, Diebold K, Friedl W, Propping P: Platelet MAO activity in patients with affective psychosis and their first degree relatives. Pharmacopsychiatry 1981; 14: 87.CrossRefGoogle Scholar
  54. Mayer-Gross W, Slater E, Roth M: Clinical Psychiatry. Baltimore, MD: William and Wilkins 1954.Google Scholar
  55. Mendlewicz J: The age factor in depressive illness: Some genetic considerations. J Gerontol 1976; 31: 300.PubMedCrossRefGoogle Scholar
  56. Mendlewicz J, Simon P, Sevy S, et al: Polymorphic DNA marker on X chromosome and manic depression. Lancet 1987; is 1230–1232.Google Scholar
  57. Murphy DL, Weiss R: Reduced platelet monoamine oxidase activity in blood platelet from bipolar depressed patients. Am J Psychiatry 1972; 128: 1351.PubMedGoogle Scholar
  58. Myers JK, Weissman M, Tischler GC, et al: Six-month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984; 41: 959–969.PubMedCrossRefGoogle Scholar
  59. Nemeroff CB, Widerlov E, Bissette G, et al: Elevated concentration of CSF corticotropin-releasing-factor-like immunoreactivity in depressed patients. Science 1984; 226: 1342–1344.PubMedCrossRefGoogle Scholar
  60. Nemeroff CB, Simon JS, Haggerty JJ, Evans DL: Antithyroid antibodies in depressed patients. Am J Psychiatry 1985; 142: 840–843.PubMedGoogle Scholar
  61. Nemeroff CB: The neurobiology of aging and the neurobiology of depression: Is there a relationship? Neurobiol Aging 1988; 9: 120–122.PubMedCrossRefGoogle Scholar
  62. Nemeroff CB, Knight DL, Krishman KRR, et al: Marked reduction in the number of platelet-titriated imipramine binding sites in geriatric depression. Arch Gen Psychiatry 1988; 45: 919–923.PubMedCrossRefGoogle Scholar
  63. Nemeroff CB, Owens MJ, Bissette G, et al: Reduced corticotropin-releasing factor binding sites in the frontal cortex of suicides. Arch Gen Psychiatry 1988; 45: 577–579.PubMedCrossRefGoogle Scholar
  64. Nemeroff CB, Evans DL: Thyrotropin-releasing hormone (TRH), the thyroid axis and affective disorder. Ann NY Acad Sci 1989; 533: 304–310.CrossRefGoogle Scholar
  65. Perry EK, et al: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1: 189.PubMedCrossRefGoogle Scholar
  66. Prange AJ, Wilson IC, Rabon AM, and Lipton MA: Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126: 457–469.PubMedGoogle Scholar
  67. Prange AJ, Wilson IC, Lara PP, Alltop LB, Breese GR: Effects of thyrotropinreleasing hormone in depression. Lancet 1972; 1: 999–1002.CrossRefGoogle Scholar
  68. Prange AJ, Wilson IC, Lynn CW, Alltop LB, Strikeleather RA: L-tryptophan in mania: Contribution to the permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974; 30: 56–62.PubMedCrossRefGoogle Scholar
  69. Prinz PN, Peskind ER, Vitaliano PR, et al: Changes in the sleep and waking EEG’s of nondemented and demented elderly subjects. J Am Geriat Soc 1982; 30: 86–93.PubMedGoogle Scholar
  70. Rao VP, Krishnan KRR, Goli V, Saunders WB, et al: Neuroanatomic changes and hypothalamo-pituitary-adrenal axis abnormalities. Biol Psychiatry 1989; 26: 729–732.PubMedCrossRefGoogle Scholar
  71. Rao SM, Mittenberg W, Bernandin L, et al: Neuropsychological test findings in subjects with leukoaraiosis. Arch Neurol 1989; 46: 40–44.PubMedCrossRefGoogle Scholar
  72. Reus VI, Joseph MS, Dallman MF: ACTH levels after the dexamethasone suppression test in depression. N Engl J Med 1982; 303: 228–229.Google Scholar
  73. Reynolds CF, Kupfer DJ: Sleep research in affective illness: State of the art circa 1987. Sleep 1987; 10: 199–215.PubMedGoogle Scholar
  74. Reynolds CF, Kupfer DJ, Houck PR, et al: Reliable discrimination of elderly depressed and demented patients by EEG sleep data. Arch Gen Psychiatry 1988; 45: 258–264.PubMedCrossRefGoogle Scholar
  75. Reynolds CF, Perel JM, Frank E, et al: Open-trial maintenance nortriptyline in late-life depression: Survival analysis and preliminary data on the use of REM latency as a predictor of recurrence. Psychopharmacol Bull 1989; 25: 129–132.PubMedGoogle Scholar
  76. Risch SC, Lewine RJ, Kahn NH, et al: Limbic-hypothalamic-pituitary-adrenal axis activity and ventricular-to-brain ratio studies in affective illness and schizophrenia Neuropsychopharmacology 1992; 6 (2): 95–100.PubMedGoogle Scholar
  77. Robinson DS, Nies A, Davis JN, et al: Aging, monoamines and monoamine oxidase. Lancet 1972; 1: 290.PubMedCrossRefGoogle Scholar
  78. Robinson DS, Sourkes TL, Nies A, et al: Monoamine metabolism in human brain. Arch Gen Psychiatry 1977; 34: 89.PubMedCrossRefGoogle Scholar
  79. Rush AJ, Erman MK, Giles DG, et al: Polysomnographic findings in recently drug-free and clinically remitted depressed patients. Arch Gen Psychiatry 1986; 43: 878–884.PubMedCrossRefGoogle Scholar
  80. Sachar EJ, Hellman L, Fukushima DK, Gallager RF: Cortisol production in depressive illness. Arch Gen Psychiatry 1970; 23: 189–298.CrossRefGoogle Scholar
  81. Salomon A, Yeates AE, Burger PC, Heinz R: Subcortical arteriosclerotic encephalopathy: Brainstem findings with MR imaging. Radiology 1987; 165: 625–629.PubMedGoogle Scholar
  82. Samorajski T, Rodsten C, Ordy JM: Changes in behavior, brain, and neuroendocrine chemistry with age and stress in C57BL/6J male mice. J Gerontol 1971; 26: 168.PubMedCrossRefGoogle Scholar
  83. Schildkraut JJ: Catecholamine hypothesis of affective disorders. Am J Psychiatry 1965; 122: 509.PubMedGoogle Scholar
  84. Sherman B, Pfohl B, Winokur G: Circadian analysis of plasma cortisol levels before and after dexamethasone administration in depressed patients. Arch Gen Psychiatry 1984; 41: 271–275.PubMedCrossRefGoogle Scholar
  85. Slater E, Cowie V: The Genetics of Mental Disorders. London: Oxford University Press, 1971.Google Scholar
  86. Slotkin TA, Whitmore WL, Barnes GA, et al: Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression. Biol Psychiatry 1989; 25: 687–691.PubMedCrossRefGoogle Scholar
  87. Vijayashankar N, Brodie H: A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J Neuropathol Exper Neurol 1979; 38: 490–497.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Charles B. Nemeroff
    • 1
  • P. Rodrigo Escalona
    • 2
  • K. Ranga
    • 2
  • R. Krishnan
    • 2
  • Charles F. ReynoldsIII
    • 3
  1. 1.Department of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlantaUSA
  2. 2.Department of PsychiatryDuke University Medical CenterDurhamUSA
  3. 3.Department of Psychiatry, University of PittsburghWestern Psychiatric Institute and ClinicPittsburghUSA

Personalised recommendations